Stemedica Cell Technologies, Inc. v. Mohammed

CourtDistrict Court, S.D. California
DecidedJune 25, 2020
Docket3:19-cv-01214
StatusUnknown

This text of Stemedica Cell Technologies, Inc. v. Mohammed (Stemedica Cell Technologies, Inc. v. Mohammed) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Stemedica Cell Technologies, Inc. v. Mohammed, (S.D. Cal. 2020).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 STEMEDICA CELL Case No.: 3:19-cv-01214-WQH-BLM TECHNOLOGIES, INC., a 12 Nevada corporation, ORDER 13 Plaintiff, 14 v. 15 ABDULAZIZ BIN MOHAMMED, a natural person; 16 JOSEPH ZIA, a natural person; 17 and DOES 2-10, 18 Defendants. 19 HAYES, Judge: 20 The matter pending before the Court is the Motion to Dismiss filed by Defendant 21 Joseph Zia. (ECF No. 15). 22 I. PROCEDURAL BACKGROUND 23 On June 28, 2019, Plaintiff Stemedica Cell Technologies, Inc. initiated this action 24 by filing a Complaint against Defendants Abdulaziz Bin Mohammed and DOES 1-10. 25 (ECF No. 1). 26 On January 22, 2020, Plaintiff filed an Amended Complaint against Defendants 27 Abdulaziz Bin Mohammed, Joseph Zia, and DOES 2-10. (ECF No. 7). Plaintiff alleges 28 1 that Defendant Mohammed and his agent Defendant Zia violated a Common Stock 2 Purchase Agreement (the “CSPA”) by failing to purchase 27,000,000 shares of Plaintiff’s 3 common stock. See id. at 3-6. Plaintiff brings the following nine causes of action: (1) 4 breach of written contact against Defendant Mohammed; (2) breach of implied contact 5 against Defendant Mohammed; (3) breach of implied covenant of good faith and fair 6 dealing against Defendant Mohammed; (4) intentional misrepresentation against 7 Defendants Mohammed and Zia; (5) promissory fraud against Defendants Mohammed and 8 Zia; (6) promissory estoppel against Defendants Mohammed and Zia; (7) negligent 9 misrepresentation against Defendants Mohammed and Zia; (8) fraud in the purchase of 10 securities pursuant to 17 C.F.R. §240.10b-5 against Defendants Mohammed and Zia; and 11 (9) right to attach order and a writ of attachment against Defendant Mohammed. See id. at 12 6-12. Plaintiff seeks general, special, and exemplary damages; interest; attorneys’ fees and 13 costs; “a right to attach order and writ of attachment in the amount of $270,000,000.00, 14 plus interest at the rate of ten percent (10%) per annum until paid …”; and “other and 15 further relief as this Court may deem just and proper.” Id. at 12-13. 16 On April 17, 2020, Defendant Zia filed a Motion to Dismiss Plaintiff’s fourth, fifth, 17 sixth, seventh, and eighth causes of action for failure to state a claim upon which relief can 18 be granted pursuant to Federal Rule of Civil Procedure 12(b)(6). (ECF No. 15).1 On May 19 12, 2020, Plaintiff filed a Response in opposition. (ECF No. 16).2 On May 19, 2020 20 Defendant Zia filed a Reply (ECF No. 17) and an Objection (ECF No. 18).3 21 II. ALLEGATIONS OF THE AMENDED COMPLAINT 22 On March 12, 2015, Plaintiff and Defendant Mohammed entered into a CSPA. See 23 ECF No. 7 at 3. The CSPA provided, in relevant part, 24 25 1 Defendant Zia requests the Court to take judicial notice of Exhibits 1, 2, and 3 to the Declaration of 26 Defendant Zia. See ECF No. 15-2. The Court has not considered these exhibits in resolving this Order. 2 Plaintiff requests the Court to take judicial notice of Exhibits 1 and 2 to Plaintiff’s Response in 27 opposition. See ECF No. 16-1. The Court has not considered these exhibits in resolving this Order. 3 Defendant Zia objects to Plaintiff’s request for judicial notice (ECF No. 16-1). See ECF No. 18. The 28 1 (a) for [Plaintiff] to sell to [Defendant Mohammed] and [Defendant Mohammed] to buy from [Plaintiff] 27,000,000 shares of common stock in 2 [Plaintiff] at a purchase price of ten dollars ($10.00) per share; and (b) for a 3 closing to take place at [Plaintiff]’s offices in San Diego.

4 Id. at 3-4. 5 The CSPA contained representations and warranties on behalf of each party. 6 For his part, [Defendant Mohammed] represented and warranted that he had substantial experience in evaluating and investing in private placement 7 transactions of securities in companies similar to [Plaintiff], was capable of 8 evaluating the merits and risks of his investment in [Plaintiff], understood and acknowledged that his investment was highly speculative and involved 9 substantial risks, could bear the economic risk of his investment, was able 10 without impairing his financial condition to suffer a complete loss of his investment, had had all access to all data he thought necessary in order to 11 commit to the investment memorialized in the CSPA and was satisfied with 12 it, and was an “accredited investor” within the meaning of Regulation D, Rule 501(a) promulgated by the U.S. Securities and Exchange Commission. 13

14 Id. at 4. 15 “The CSPA supplied as the rule of decision in any after-arising dispute the 16 substantive law of the State of California, without regard to conflicts of law principles, and 17 provided that this Court would have exclusive jurisdiction of any dispute arising out of or 18 related to the CSPA.” Id. “The CSPA also included a clause stating that delay in exercising 19 any remedies for breach or default could not be construed as an impairment of the right to 20 pursue those remedies at a later time.” Id. “The CSPA forbade any amendments to its 21 terms except via a mutually-signed writing, and expressly prohibited an effort to ‘go 22 outside’ the CSPA by positing any purported amendment (whether oral, emailed, or 23 otherwise) that did not satisfy that clause.” Id. 24 Contemporaneously with the execution of the CSPA, [Defendant Mohammed] signed a document entitled “letter of confirmation & 25 authorization,” which appended wire instructions for the transfer of the first 26 installment of the cash owing from [Defendant Mohammed], in the amount of $180 million, from [Defendant Mohammed] to [Plaintiff]. This document 27 identified [Defendant] Zia as [Defendant Mohammed]’s agent for purposes of 28 the transfer. The attached wire transfer instructions listed as the originating 1 bank a Bank of America branch on Mia Sorrento Place. [Defendants] Zia and [Mohammed] both signed this document. 2

3 On [Defendant Mohammed]’s behalf, [Defendant] Zia delivered a letter to [Plaintiff] promising the wiring of the cash, on July 2, 2015. In this letter, 4 [Defendant] Zia acknowledged the establishment of a limited liability 5 company for the purpose of holding [Defendant Mohammed]’s $270,000,000.00 for release to [Plaintiff] pending satisfaction of certain 6 “contingencies.” The “contingencies” listed in [Defendant] Zia’s letter, 7 however, were and are parol evidence and an invalid effort to renegotiate the terms of the CSPA (whose § 6.9 embodies the parties’ agreement that the 8 CSPA constituted the “full and entire understanding and agreement between 9 the parties”).

10 Afterward, [Defendant Mohammed] did not perform. He proffered excuses 11 for not doing so. These included health problems (a pair of heart attacks) and family issues (the illness and death of his father). The heart attacks, he said, 12 required his hospitalization and put him out of commission for a period of 13 months. Another excuse was delay [Defendant Mohammed] was experiencing in receiving an inheritance from his father’s estate. 14

15 In multiple telephone conversations with members of [Plaintiff]’s board of directors and management, however, [Defendant Mohammed] repeatedly 16 affirmed his intent to honor the CSPA. [Defendant] Zia, his agent, did the 17 same. In the meanwhile, on information and belief, [Defendant Mohammed] brought cash into the U.S. by transferring it to a Citibank account in Beverly 18 Hills from a Barclays Bank account in London. Although he could have used 19 some or all of this cash in order to honor his commitment under the CSPA, he did not do so. 20

21 Minutes of [Plaintiff]’s directors’ meetings reflect [Plaintiff]’s contemporaneous reliance on [Defendant Mohammed]’s commitment to 22 [Plaintiff] as memorialized in the CSPA.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Merck & Co. v. Reynolds
559 U.S. 633 (Supreme Court, 2010)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Bartlett v. Strickland
556 U.S. 1 (Supreme Court, 2009)
United States v. Spector
55 F.3d 22 (First Circuit, 1995)
Conservation Force v. Salazar
646 F.3d 1240 (Ninth Circuit, 2011)
Maguire v. Hibernia Savings & Loan Society
146 P.2d 673 (California Supreme Court, 1944)
Hensler v. City of Glendale
876 P.2d 1043 (California Supreme Court, 1994)
Moss v. U.S. Secret Service
572 F.3d 962 (Ninth Circuit, 2009)
Hatch v. Collins
225 Cal. App. 3d 1104 (California Court of Appeal, 1990)
Bly-Magee v. California
236 F.3d 1014 (Ninth Circuit, 2001)
Vess v. Ciba-Geigy Corp. USA
317 F.3d 1097 (Ninth Circuit, 2003)
Albano v. Shea Homes Ltd. Partnership
634 F.3d 524 (Ninth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Stemedica Cell Technologies, Inc. v. Mohammed, Counsel Stack Legal Research, https://law.counselstack.com/opinion/stemedica-cell-technologies-inc-v-mohammed-casd-2020.